Clinical TrialJul 13, 2026, 07:51 AM
Kamada Highlights Positive CYTOGAM Study Results for Lung Transplants
AI Summary
Kamada Ltd. highlighted positive results from an Investigator-Initiated Study on its product CYTOGAM® (Cytomegalovirus Immune Globulin) presented at the 2026 ISHLT Annual Meeting. The study found that CYTOGAM use was associated with improved clinical outcomes in CMV high-risk lung transplant recipients, including less activated innate immune cells and blunted lung injury in models. These findings suggest CYTOGAM's potential for immune modulation and are expected to support increased product utilization.
Key Highlights
- CYTOGAM study results presented at the 2026 ISHLT Annual Meeting showed improved clinical outcomes for CMV high-risk lung transplant recipients.
- Patients receiving CMVIG prophylaxis had less activated innate immune cells compared to those who did not.
- Non-clinical in-vivo models indicated CYTOGAM blunted lung injury and improved mortality.
- Findings suggest CYTOGAM may offer immune modulation benefits beyond just CMV viremia control.
- The results are consistent with a prior Investigator-Initiated Study presented at IDWeek 2023.
- Kamada expects these data to support increased product utilization for CYTOGAM.
Price Impact
More from KMDA